Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Cash & Equivalents (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Cash & Equivalents over the past 10 years, most recently at $9.7 million for Q4 2023.

  • For Q4 2023, Cash & Equivalents rose 154.79% year-over-year to $9.7 million; the TTM value through Dec 2023 reached $9.7 million, up 154.79%, while the annual FY2023 figure was $9.7 million, 154.79% up from the prior year.
  • Cash & Equivalents for Q4 2023 was $9.7 million at Corbus Pharmaceuticals Holdings, up from $2.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $89.9 million in Q1 2019 and troughed at $1.6 million in Q1 2020.
  • A 5-year average of $30.0 million and a median of $15.6 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 4820.51% in 2019 and later crashed 98.24% in 2020.
  • Year by year, Cash & Equivalents stood at $31.7 million in 2019, then skyrocketed by 169.09% to $85.4 million in 2020, then crashed by 78.63% to $18.3 million in 2021, then tumbled by 79.16% to $3.8 million in 2022, then soared by 154.79% to $9.7 million in 2023.
  • Business Quant data shows Cash & Equivalents for CRBP at $9.7 million in Q4 2023, $2.0 million in Q3 2023, and $6.6 million in Q2 2023.